Target intelligence / Profile preview

Immunoglobulin heavy variable 2-5 (IGHV2-5)

Target
IGHV2-5
Molecular classification
Immunoglobulin variable region, Other (component of antigen receptor)
01

Overview

Immunoglobulin heavy variable 2-5 (IGHV2-5) encodes the variable (V) region of the immunoglobulin heavy chain, a critical part of the antigen-binding site formed in B cell-derived antibodies. The IGHV2-5 gene is one member of the IGHV multigene family located within the immunoglobulin heavy-chain (IGH) locus, which undergoes recombination with diversity (D) and joining (J) segments during B cell development to generate antibody diversity. The V region, comprising three complementarity-determining regions (CDRs) and four framework regions, is responsible for specific antigen recognition and binding, shaping the adaptive immune response. IGHV2-5 features multiple allelic variants, contributing to the diversity of the antibody repertoire in humans; sequence polymorphisms, particularly in CDR1 and CDR2, affect antigen affinity and specificity. IGHV2-5 is not a therapeutic target (like receptor or enzyme); instead, it is a gene segment providing building blocks for antibody molecules. No drugs specifically target IGHV2-5, nor is it a biomarker for disease or drug response. Its clinical relevance is indirect—through its contribution to normal and abnormal antibody responses.

Other names
IGHV2-5Ig heavy chain V-II region HEIg heavy chain V-II region MCEIGHV25VHIg heavy chain V-II region 5immunoglobulin heavy chain variable region
02

Mechanism of action

Not applicable (IGHV2-5 is not directly targeted by drugs; its role is inherent to the antigen-binding diversity in antibodies.)

03

Biological functions

Antigen bindingImmune response (immunoglobulin-mediated immune response)Formation of antigen-binding site in antibodies
04

Disease associations

Other (germline variants contribute to antibody diversity; no direct pathogenic or therapeutic disease role identified)
05

Safety considerations

None known (no specific safety issues reported for this gene segment; general immune dysregulation could be theoretically related to immunoglobulin gene rearrangements, but not to IGHV2-5 specifically.)
06

Interacting drugs

None known (IGHV2-5 is not a typical drug target; no approved drugs directly target this variable gene segment.)
07

Biomarkers

None established (IGHV2-5 sequence usage can be measured in immune repertoire profiling, but it is not established as a clinical biomarker.)

Beyond the preview

Go deeper on Immunoglobulin heavy variable 2-5 (IGHV2-5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy variable 2-5 (IGHV2-5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call